financetom
Business
financetom
/
Business
/
Expect 40-50% revenue growth in FY24: Paras Defence & Space Technologies
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Expect 40-50% revenue growth in FY24: Paras Defence & Space Technologies
May 17, 2023 3:18 AM

Paras Defence & Space Technologies reports a steady fourth quarter with revenues 6 percent higher at Rs 65 crore. Earnings before interest, tax, depreciation and amortization declined 2 percent to Rs 17 crore. Operating profit margin at 26.4 percent stood 240 bps lower than 28.8 percent clocked in same quarter last year. Net profits, although jumped 5 percent in the fourth quarter of financial year 2022-23.

Share Market Live

NSE

The current order book is in excess of Rs 550 crore and will start building further in the next quarter. Amit Mahajan, Paras Defence & Space Technologies, in an interaction with CNBC-TV18 on May 17 expects 40 to 50 percent revenue growth in FY24. This is double of the 20 percent revenue growth clocked in FY23. The high revenue growth of FY24 is supported by a large order book. The margins are expected to be at similar levels or marginally better than FY23.

Also read: Paras Defence signs MoU MeiTY Research Lab for development of various technologies

Drones contribute less than 20 percent of company's order book. Furthermore, the company had received DGCA Type Certificate for agricultural drones. "Our technology in agri drones is much superior than the other agri drones available in market" Mahajan said. The company is manufacturing agri drones in-house and hence have been able to clock healthy margins in this segment. Paras Aerospace is expected to clock better growth than Paras Defence in FY24.

Exports are expected to contribute 10 to 20 percent of the company's revenues and by FY25, drones shall contribute 25 percent of total revenues.

Paras Defence & Space Technologies stock is 1 percent lower at noon on Wednesday and has fallen 13 percent in past one year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Palo Alto Networks To Acquire Chronosphere For $3.35 Billion
BRIEF-Palo Alto Networks To Acquire Chronosphere For $3.35 Billion
Nov 19, 2025
Nov 19 (Reuters) - Palo Alto Networks Inc ( PANW ): * PALO ALTO NETWORKS TO ACQUIRE CHRONOSPHERE, NEXT-GEN OBSERVABILITY LEADER, FOR THE AI ERA * PALO ALTO NETWORKS INC ( PANW ) - ACQUISITION VALUED AT $3.35 BILLION Source text: Further company coverage: ...
ACCO GROUP HOLDINGS LIMITED ANNOUNCES PARTIAL EXERCISE OF UNDERWRITERS’ OVER-ALLOTMENT OPTION
ACCO GROUP HOLDINGS LIMITED ANNOUNCES PARTIAL EXERCISE OF UNDERWRITERS’ OVER-ALLOTMENT OPTION
Nov 19, 2025
Hong Kong, Nov. 19, 2025 (GLOBE NEWSWIRE) -- ACCO GROUP HOLDINGS LIMITED ( ACCL ) (the “Company”), a corporate services provider headquartered in Hong Kong, today announced the partial exercise of the over-allotment option (the “Over-Allotment Option”) by the underwriters of Company’s initial public offering (the “Offering”) to purchase an additional 49,900 ordinary shares of the Company at the initial...
Allstate Insider Sold Shares Worth $3,583,277, According to a Recent SEC Filing
Allstate Insider Sold Shares Worth $3,583,277, According to a Recent SEC Filing
Nov 19, 2025
04:14 PM EST, 11/19/2025 (MT Newswires) -- Thomas J Wilson, Director, Chairman, President & CEO, on November 17, 2025, sold 16,807 shares in Allstate ( ALL ) for $3,583,277. Following the Form 4 filing with the SEC, Wilson has control over a total of 947,336 common shares of the company, with 161,619 shares held directly and 785,717 controlled indirectly. SEC...
Galectin Therapeutics Insider Sold Shares Worth $478,849, According to a Recent SEC Filing
Galectin Therapeutics Insider Sold Shares Worth $478,849, According to a Recent SEC Filing
Nov 19, 2025
04:10 PM EST, 11/19/2025 (MT Newswires) -- Jack W Callicutt, Chief Financial Officer, on November 17, 2025, sold 77,920 shares in Galectin Therapeutics ( GALT ) for $478,849. Following the Form 4 filing with the SEC, Callicutt has control over a total of 7,614 common shares of the company, with 7,614 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/xslF345X05/form4.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved